## LRCX: Lam Research Corporation - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.4% in lower entry zone (3.0-6.0%), top quartile (84th pct) cross-sectional ranking. Short-term MRS_5 (2.3%) confirms momentum alignment. Strong momentum (+3.2% 5-day acceleration). Outperforming sector by 3.3%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($155.65)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Lam Research stock hits all-time high at 167.29 USD**
- Source: Investing.com | 20251210T190824 | Bullish | Relevance: 99%
-  Lam Research (NASDAQ:LRCX) stock has reached an all-time high of $167.29, reflecting a 123.4% increase over the past year. The company showcases strong fundamentals with a market capitalization of $209.15 billion, a P/E ratio of 36.36, and a 25.66% revenue growth. Analysts have raised price targets for LRCX, citing strong demand and growth opportunities in the wafer fabrication equipment sector.

**2. Lam Research (NASDAQ:LRCX) Trading Up 1.9% - Here's Why**
- Source: MarketBeat | 20251209T224021 | Bullish | Relevance: 98%
-  Lam Research (NASDAQ:LRCX) saw its share price increase by 1.9% during mid-day trading on Tuesday, closing at $165.81. This surge comes despite trading volume being 31% below its average daily volume, and follows the company reporting better-than-expected quarterly results with $1.26 EPS and $5.32 billion in revenue. Analysts remain largely positive on LRCX, with a "Moderate Buy" consensus rating, though the average price target is below the current trading price.

**3. Intact Investment Management Inc. Decreases Stock Holdings in Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251211T122617 | Somewhat-Bullish | Relevance: 98%
-  Intact Investment Management Inc. significantly reduced its stake in Lam Research Corporation by 53.9% during the second quarter, selling 34,200 shares and holding 29,200 shares valued at $2.84 million. Despite this, several other institutional investors, including Vanguard Group Inc., State Street Corp, JPMorgan Chase & Co., and Geode Capital Management LLC, increased their positions in the semiconductor company. Lam Research reported strong Q3 earnings, beating analyst estimates with $1.26 EPS and $5.32 billion in revenue, and announced a quarterly dividend of $0.26 per share.

**4. Federated Hermes Inc. Has $30.86 Million Stock Holdings in Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251210T095245 | Neutral | Relevance: 98%
-  Federated Hermes Inc. significantly reduced its stake in Lam Research Corporation by 46.3% in the second quarter, bringing its total holdings to $30.86 million. Despite this, other institutional investors like Vanguard Group Inc., JPMorgan Chase & Co., and Geode Capital Management LLC increased their positions in the semiconductor company. Wall Street analysts maintain a "Moderate Buy" consensus rating for Lam Research, with a consensus price target of $152.87.

**5. Axa S.A. Raises Holdings in Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251209T083033 | Somewhat-Bullish | Relevance: 98%
-  Axa S.A. increased its stake in Lam Research Corporation, a semiconductor company, by 26% in Q2, bringing their total to 793,787 shares valued at approximately $77.3 million. Despite positive earnings and revenue performance, insiders have been net sellers of the stock, while several other institutional investors also adjusted their positions. The company recently announced a quarterly dividend of $0.26 per share, and analysts currently hold a "Moderate Buy" consensus rating with a target price of $152.87.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $158 | $137 | +15% |
| 2025-11-25 | UBS | $175 | $165 | +6% |
| 2025-11-12 | Citigroup | $190 | $175 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 6 ($14.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+0.3%)
- Blackrock Inc.: 9.9% (+1.7%)
- JPMORGAN CHASE & CO: 4.8% (+47.4%)
- State Street Corpora: 4.8% (+0.4%)
- Geode Capital Manage: 2.7% (-0.5%)

### Key Risks

1. Heavy insider selling: $14M sold (6 transactions in 90 days).
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.39 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 62%, ROA 20%, margin 30%). Balance sheet: strong liquidity (2.2x), $1.6B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($14.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $212.7B |
| Beta | 1.78 |
| 52W Range | $56.32 - $169.69 |
| Short Interest | 3.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.39 |
| Forward P/E | 30.2 |
| Current P/E | 34.9 |
| YoY Growth | 15.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.2% to 4.4% (+3.2% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 84th percentile. MRS_5 at 2.3% confirms short-term momentum alignment. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.38), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.41% (CS: 84) | Strong |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | 1.38 | Bullish |
| vs SMA20 | 1.092x | Above |
| vs SMA50 | 1.109x | Above |
| vs SMA200 | 1.592x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $168.71
- **Stop Loss:** $155.65 (7.7% risk)
- **Target:** $188.30 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 105
- **Position Value:** $17,714.55
- **Portfolio %:** 17.71%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-28 (Est: $1.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.22 | $1.26 | +3.3% |
| 2025Q2 | $1.21 | $1.33 | +10.4% |
| 2025Q1 | $1.00 | $1.04 | +4.1% |
| 2024Q4 | $0.88 | $0.91 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*